Hythiam Establishes Treatment Network for Servicing European Market with Third Swiss Licensee, Privatklinik Meiringen; Licensees in Lugano, Meiringen/Berne, and Geneva Cater to European Clientele.

LOS ANGELES -- Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company licensing the PROMETA(TM) physiological protocols designed to treat alcohol, methamphetamine and cocaine dependence, announced today that Privatklinik Meiringen, a private hospital with 180 beds based in Switzerland, has been signed as the third European licensee for PROMETA. Treatments will be offered at its clinic and on an outpatient basis by Professor Michael Soyka. The addition of this site to Hythiam's existing European licensees in Geneva and Lugano completes Hythiam's initial network of treatment destinations for servicing the European market.

"Currently our therapists employ cognitive behavioral therapy with patients and experience and organization-oriented therapies are supplements to that mode. In our work, we are always examining the current scientific level of knowledge, and use that knowledge with realizations gleaned from clinical experiences along with proven methods from complementary medicine. We are very open to new biologically based treatments such as PROMETA," said Professor Michael Soyka, Medical Director of Privatklinik Meiringen, and a widely regarded addiction medicine specialist and professor at University of Munich/Germany in the Department of Psychiatry. "Through our incorporation of the PROMETA protocols, patients in Switzerland will now have access to the latest innovation in substance dependency treatment."

"Switzerland is well-regarded worldwide as a destination for and creator of high quality, innovative medical treatment and Privatklinik Meiringen has long been regarded in Europe as a leading provider of substance dependence treatment. We are pleased that PROMETA has been recognized by respected treatment providers, and by the most regarded clinicians and researchers, like Professor Michael Soyka, in a country that is considered a leader in healthcare in Europe and beyond," said Terren Peizer, Hythiam's Chairman and CEO. "Additionally, Switzerland is representative of several European cultures and our licensees are strategically situated in Lugano, Meiringen/Berne, and Geneva in order to provide ready access to the PROMETA Protocols for the greater European continent."

About Privatklinik Meiringen

Privatklinik Meiringen is a historic private hospital with 180 beds. Substance dependency is treated there on an in or outpatient basis. Privatklinik Meiringen seeks to diagnose, treat and offer psychological support for patients with substance dependence and psychiatric disorders. The private hospital is open to those in need of treatment and accepts all insurances from within Switzerland and foreign countries. Depending upon a patient's situation, treatment can take place on an in or outpatient basis. Medical Director, Professor Soyka has been the author for several textbooks on the subject of alcohol and drug dependence. He is one of Europe's leading authorities on medical treatments for substance dependency and has authored numerous papers on the subject of alcohol and drug dependence. For further information, please click on www.pm-klinik.ch.

About PROMETA(TM)

Hythiam's PROMETA(TM) treatment protocols are designed for use by healthcare providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamine, as well as combinations of these drugs. The PROMETA treatment protocols comprise nutritional supplements, FDA-approved oral and IV medications used off-label and separately administered in a unique dosing algorithm, as well as psychosocial or other recovery-oriented therapy chosen by the patient and his or her treatment provider. As a result, PROMETA represents an innovative approach to managing alcohol, cocaine, or methamphetamine dependence that is designed to address physiological, nutritional, and psychosocial aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained recovery. For further information, please click on www.prometainfo.com.

About Hythiam, Inc.

Hythiam(R) is a healthcare services management company focused on delivering solutions for those suffering from alcoholism and other substance dependencies. Hythiam researches, develops, licenses and commercializes innovative physiological, nutritional, and behavioral treatment protocols that seek to address substance dependence. Additionally, Hythiam provides proprietary administrative services to assist physicians and facilities with staff education, marketing and outreach support, and outcomes tracking for data analysis. For further information, please click on www.hythiam.com.

Forward-Looking Statements 

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.